Login / Signup

Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial.

Qiang ZhouZhiqiang WangHeming WangZhidong ChenXiaoyi LiXiangrong DaiYong ZhangXiaohui YuRenpeng ZhouWei Hu
Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
ClinicalTrials.gov identifier: NCT04627116.
Keyphrases
  • open label
  • phase iii
  • phase ii
  • study protocol
  • clinical trial
  • randomized controlled trial
  • double blind
  • placebo controlled